Clinical trials: Varenicline
Smoking Cessation
Post Marketing Surveillance Study of Champix in Smoking Cessation for Filipino Patients
The primary objective of this Post-Marketing Study is to monitor the safety of a novel smoking cessation drug Varenicline (Champix™) 0.5 mg and 1 mg tablets as used in clinical practice for 12 weeks among Filipino smokers.
- Trial name
- NCT00794365
- Testing
- Varenicline
- Volunteers
- 330 people
- Sponsor
- Pfizer
Smoking Cessation
Randomized Study Comparing the Efficacy and Safety of Varenicline Tartrate to Placebo in Smoking Cessation When Subjects Are Allowed to Set Their Own Quit Date
The hypothesis is that varenicline will be effective (compared with placebo) for smoking cessation when subjects are allowed to set their own quit date within the first 5 weeks of treatment.
- Trial name
- NCT00691483
- Testing
- varenicline
- Where
- 33 sites in United States, Argentina and 12 more
- Volunteers
- 659 people
- Sponsor
- Pfizer
Healthy, Non-Smoking
Evaluation of Varenicline Safety, Tolerability, Pharmacokinetics and Pro-Cognitive Effects in Healthy Elderly Non-Smoking Subjects
1. Characterize the tolerability and safety of repeated doses of varenicline in healthy non-smoking elderly subjects. 2. Describe the steady state pharmacokinetics of varenicline in healthy non-smoking elderly subjects. 3.
- Trial name
- NCT00694044
- Testing
- varenicline
- Where
- 2 sites in United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Pfizer
Smoking Cessation, Pharmacokinetics
A Clinical Trial to Compare Pharmacokinetics of the "CDFF0318" and "Champix Tab. 1mg"
A Phase 1 Clinical Trial to Compare and Evaluate Safety and Pharmacokinetic Characteristics after Administration of the "CDFF0318" and "Champix Tab. 1mg (Varenicline tartrate)" in Healthy Male Volunteers
- Trial name
- NCT04631874
- Testing
- CDFF0318, Champix
- Where
- South Korea
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- CTC Bio, Inc.
Smoking Cessation
A Multi-National Study To Assess How Effective And Safe The Smoking Cessation Medicine Varenicline Is In Smokers Who Have Already Tried Varenicline In The Past As A Prescription Medicine From Their Usual Healthcare Provider
The main purpose of this study is to compare the effectiveness and safety of the re-treatment of smokers with varenicline with placebo for smoking cessation during the last 4 weeks of a 12 week course of treatment.
- Trial name
- NCT01244061
- Testing
- Varenicline
- Where
- 37 sites in United States, Australia and 6 more
- Volunteers
- 498 people
- Sponsor
- Pfizer
Smoking Cessation
Study Evaluating The Safety And Efficacy Of Varenicline and Bupropion For Smoking Cessation In Subjects With And Without A History Of Psychiatric Disorders
This study is being conducted to assess varenicline and bupropion as aids to smoking cessation treatment in subjects with and without an established diagnosis of major psychiatric disorder and to characterize the neuropsychiatric…
- Trial name
- EAGLES (NCT01456936)
- Testing
- varenicline tartrate, bupropion hydrochloride, Nicotine Replacement Therapy Patch
- Where
- 156 sites in United States, Argentina and 14 more
- Volunteers
- 8,144 people, healthy volunteers welcome
- Sponsor
- Pfizer
Smoking Cessation
A Study To Evaluate The Efficacy And Safety Of Varenicline Compared To Placebo For Smoking Cessation Through Reduction
This study will determine whether varenicline is safe and helps people to quit smoking through reduction when they are not willing/able to make an abrupt quit attempt.
- Trial name
- NCT01370356
- Testing
- Varenicline Tartrate
- Where
- 65 sites in United States, Australia and 8 more
- Volunteers
- 1,510 people
- Sponsor
- Pfizer
Dry Eye Disease
Efficacy of OC-01 Nasal Spray on Goblet Cell and Meibomian Gland Stimulation
The objective of this study is to evaluate the safety and effectiveness of OC-01 Nasal Spray as compared to placebo in simulating Goblet Cell and Meibomian Gland function in adult subjects with DED.
- Trial name
- NCT03688802
- Testing
- OC-01 (varenicline) nasal spray
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Oyster Point Pharma, Inc.
Dry Eye, Keratoconjunctivitis Sicca
Phase 4 Study Evaluating the Safety of the Nasal Guide With Tyrvaya
The objective of this study is to determine the safety of the nasal guide when utilized to aid in the administration of Tyrvaya (varenicline solution 0.03mg) Nasal Spray
- Trial name
- NCT05918406
- Testing
- Nasal Guide
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Oyster Point Pharma, Inc.
Alzheimer's Disease
Evaluation of the Efficacy of Varenicline on Cognition, Safety, Tolerability and Pharmacokinetics in Subjects With Mild-to-Moderate Alzheimer's Disease
1. Assess the efficacy of varenicline, relative to placebo, on a performance based measure of cognition in patients with mild to moderate Alzheimer's disease 2.
- Trial name
- NCT00744978
- Testing
- Varenicline
- Where
- 8 sites in South Korea
- Volunteers
- 66 people
- Sponsor
- Pfizer
Trigeminal Neuralgia
RP-008 in Combination With Daily Oral Varenicline for the Treatment of Trigeminal Neuralgia
The goal of this study is to evaluate if KRIYA-748 (RP-008) is safe, tolerable, and preliminary effective in treating trigeminal neuralgia (TN) when used in combination with varenicline tartrate.
- Trial name
- RELIEF (NCT07596485)
- Testing
- RP-008, Varenicline tartrate
- Where
- Canada
- Volunteers
- 24 people
- Sponsor
- Kriya Therapeutics, Inc.
Smoking Cessation
Assessing Neuropsychiatric Symptoms Including Depression, Anxiety, Irritability, and Suicidal Thoughts or Behavior in Subjects Quitting Smoking on Varenicline Tartrate or Placebo
Study objective is to compare neuropsychiatric adverse events in subjects treated with varenicline or placebo in a controlled setting where both groups are experiencing nicotine withdrawal.
- Trial name
- NCT00749944
- Testing
- varenicline
- Where
- 2 sites in United States
- Volunteers
- 110 people
- Sponsor
- Pfizer
Smoking Cessation
A 52-Week Placebo-Controlled Study Evaluating the Safety of Varenicline
The primary purpose of this study is to obtain safety information on cigarette smokers treated with 52 weeks of varenicline regardless of smoking status.
- Trial name
- NCT00143299
- Testing
- varenicline (CP-526,555)
- Where
- 9 sites in United States, Australia
- Volunteers
- 375 people
- Sponsor
- Pfizer
Smoking Cessation
Efficacy and Safety of Varenicline in Smokers With Cardiovascular Disease Who Wish to Quit Smoking
The primary purpose of this study is to determine whether or not varenicline will help people with cardiovascular disease quit smoking and to confirm it is safe in these patients.
- Trial name
- NCT00282984
- Testing
- Varenicline
- Where
- 39 sites in United States, Argentina and 13 more
- Volunteers
- 714 people
- Sponsor
- Pfizer
Smoking Cessation
12 Week Evaluation of the Safety and Efficacy of 4 Dosing Strategies of CP-526,555 and Placebo for Smoking Cessation.
The purpose of the study is to measure the safety and efficacy of four dosing strategies of CP-526,555 for 12 weeks compared with placebo for smoking cessation.
- Trial name
- NCT00150254
- Testing
- CP-526,555 (varenicline)
- Where
- 13 sites in United States
- Volunteers
- 625 people
- Sponsor
- Pfizer
Unspecified Adult Solid Tumor, Protocol Specific
Varenicline Tartrate With Telephone-Based Counseling and/or Internet-Based Counseling in Helping Adults Stop Smoking
RATIONALE: Varenicline tartrate may help people quit smoking by decreasing the symptoms of nicotine withdrawal. It is not yet known whether varenicline tartrate is more effective in helping people stop smoking when given together…
- Trial name
- NCT00301145
- Testing
- smoking cessation intervention, varenicline, counseling intervention
- Where
- 3 sites in United States
- Volunteers
- 1,200 people
- Sponsor
- SRI International
Dry Eye Disease
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of OC-01 in Adult Chinese With Dry Eye Disease
The objective of this study is to evaluate the pharmacokinetics (PK) in adult Chinese subjects with dry eye disease (DED)1 after bilateral nasal spray administration of OC-01 (varenicline solution) Nasal Spray at a concentration…
- Trial name
- NCT05576415
- Testing
- Varenicline Tartrate Nasal Spray
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Corxel Pharmaceuticals
Smoking Cessation, Stress
Efficacy and Tolerability of Combination Varenicline With Hydroxyzine as a Potential Smoking Cessation Treatment
This open-label study will evaluate hydroxyzine, a first-generation antihistamine, combined with varenicline, to help smokers abstain from smoking during a 12-week trial period by diminishing the nausea, stress, anxiety, and…
- Conditions
- Smoking Cessation, Stress, Sleep Disturbance, Nausea
- Trial name
- HAVE (NCT04188106)
- Testing
- Varenicline Pill, Hydroxyzine Pill
- Where
- 2 sites in United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Rose Research Center, LLC
Smoking Cessation
Drug Use Investigation Of Varenicline (Regulatory Post Marketing Commitment Plan)
The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the LPD (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3)factors…
- Trial name
- NCT00772941
- Testing
- Varenicline
- Volunteers
- 3,939 people
- Sponsor
- Pfizer
Smoking Cessation, Insurance Coverage
Impact Of Smoking Cessation Treatment Reimbursement On The Quit Rates In Smokers Motivated To Quit
This study is based on the hypothesis that access to smoking cessation treatment (SCT) reimbursement may significantly increase the number of successful quitters in a population of smokers motivated to quit by: 1) increasing the…
- Trial name
- ACCESSATION (NCT00818207)
- Testing
- Full Smoking Cessation Treatment Coverage (100%), No Smoking Cessation Treatment Coverage (0%)
- Where
- 56 sites in Canada
- Volunteers
- 1,380 people, healthy volunteers welcome
- Sponsor
- Pfizer